Intravenous Ascorbic Acid as an Adjuvant Therapy for Recombinant Erythropoietin in Hemodialysis Patients With Hyperferritinemia

Kidney International - United States
doi 10.1046/j.1523-1755.1999.00479.x
Full Text
Abstract

Available in full text

Categories
Nephrology
Date
Authors
Publisher

Elsevier BV

Related search

IL-7 Serum Levels and Lymphopenia in Hemodialysis Patients, Non-Responders to Recombinant Human Erythropoietin Therapy

Blood Cells, Molecules, and Diseases
Molecular MedicineHematologyMolecular BiologyCell Biology
2008English

Melatonin as an Adjuvant Therapy in Patients With Rheumatoid Arthritis

British Journal of Clinical Pharmacology
Pharmacology
2008English

Effects of Recombinant Human Erythropoietin (R-HuEPO) Treatment on Cardiovascular Hemodynamics in Hemodialysis Patients

Journal of Japanese Society for Dialysis Therapy
1989English

Study of Hemodialysis Patients Who Do Not Require Administration of Recombinant Human Erythropoietin.

Nihon Toseki Igakkai Zasshi
2000English

Single-Dose Intravenous Administration of Recombinant Human Erythropoietin Is a Promising Treatment for Patients With Acute Myocardial Infarction

Circulation Journal
MedicineCardiovascular MedicineCardiology
2010English

Eicosapentaenoic Acid as Adjuvant for Cachexia in Cancer’s Patients

International Journal of Integrated Health Sciences
2015English

Intravenous Ascorbic Acid Protocol for Cancer Patients: Scientific Rationale, Pharmacology, and Clinical Experience

Functional Foods in Health and Disease
2013English

Effectiveness of Erythropoietin in Hypertensive Hemodialysis Patients

Pharmacology and Clinical Pharmacy Research
2017English

Breast-Cancer Adjuvant Therapy With Zoledronic Acid

New England Journal of Medicine
Medicine
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy